摘要
目的 评价联苯双酯、葡醛内酯对抗结核药所致肝损害的预防和治疗效果。方法 1 2 4例住院HBsAg( +)初治浸润型肺结核随机分为两组 ,均以 2HRZE(S) / 4HR方案抗结核治疗 ,治疗组于强化期加用联苯双酯、葡醛内酯。结果 治疗组 53例 ,发生可逆性中度转氨酶增高 9例 ( 1 7.0 % ) ;对照组 71例 ,发生可逆性中度转氨酶增高 2 5例 ( 3 5.2 % ) ,两组差异显著 (P <0 .0 5)。同时观察住院HBsAg( -)初治浸润型肺结核 1 1 6例 ,发生可逆性中度转氨酶增高 1 0例 ( 8.6% )。结论 HBsAg( +)病例接受抗结核治疗易发生药物性肝损害 ,联苯双酯、葡醛内酯只对部分药物性肝损害有预防和治疗作用 ,而药物过敏反应可能在抗结核药所致药物性肝损害中起一定作用。
Objective To evaluate the efficacy of bipheny dicarboxylate and glucurolactone on prevention and treatment of antituberculous drug hepatoxicity.Methods 124 hospitalized HBsAg positive patients with pulmonary tuberculosis were randomized to bipheny dicarboxylate and glucurolactone of control group in addition to 2HRZE/4HR therapy.Results Middle level reversible serum aspartate transaminase elevation (17.0% vs 35.2% P<0.05) occurred more commonly in the 71 patients randomized to the control group. There exists statistically significant difference between the two groups.Meanwhile 116 HBsAg negative patients with pulmonary tuberculosis were observed and only 8.6% of them occurred middle level reversible serum aspartate transaminase elevation during antituberculous therapy.Conclusion Medicamentous liver lesion may occurred more commonly in HBsAg positive patients after antituberculous therapy.bipheny dicarboxylate and glucurolactone can only prevent and cure part of them.Drug anaphylactic reaction may play a role in medicamentous liver lesion.
出处
《中国防痨杂志》
CAS
2000年第2期86-87,共2页
Chinese Journal of Antituberculosis
关键词
肺结核
联苯双酯
葡醛内酯
并发症
药物性肝损害
Tuberculosis,pulmonary Bipheny Dicarboxylate Glucurolactone Drug toxicity
